| Name | Title | Contact Details |
|---|---|---|
Chris Vaughan |
Information Security Officer | Profile |
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize tirasemtiv. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy and chronic obstructive pulmonary disease. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics` specified development and commercialization participation rights.
Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics.
Introducing the most advanced platform for clinical genomic analysis… Solutions for each type of medical use Using data and machine learning to build a more accurate picture of each patient We are passionate about creating bioinformatic solutions that ...
Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
MeMed is a host response, med-tech & bioconvergence company, offering innovative diagnostic host response tests that address complex clinical dilemmas & improve patient outcomes.